Michael Jon Brown, Executive Vice President and Chief Legal Compliance Officer of Dexcom Inc (NASDAQ:DXCM), filed a Form 4 on November 18, 2026, disclosing the sale of 1,700 shares of common stock on November 16, 2026, pursuant to a 10b5-1 trading plan.

Key Highlights

  • Shares sold: 1,700 shares of Dexcom common stock were disposed of on November 16, 2026, at a price of $83.46 per share.
  • 10b5-1 plan: The sale was made under a plan adopted by Mr. Brown on November 26, 2025, intended to allow orderly disposition of his shares.
  • Remaining beneficial ownership: Following the transaction, Mr. Brown beneficially owned 95,034 shares directly.
  • Unvested RSUs included: Of the 95,034 shares, 69,053 are unvested restricted stock units from grants made on March 8, 2024, March 8, 2025, and March 8, 2026.
  • Reporting person role: Mr. Brown is identified in the filing as EVP Chief Legal Compliance Officer of Dexcom Inc.

Brown's 10b5-1 Plan Sale and Post-Transaction Holdings at Dexcom

According to the filing, Michael Jon Brown sold 1,700 shares of Dexcom Inc common stock on November 16, 2026, at $83.46 per share. The filing states that the transaction was made pursuant to a Rule 10b5-1 trading plan that Mr. Brown adopted on November 26, 2025. The form indicates this plan "allows the orderly disposition of shares owned by Mr. Brown."

Following the reported sale, Mr. Brown's direct beneficial ownership stood at 95,034 shares, according to the filing. The filing discloses that 69,053 of those shares are unvested restricted stock units. Specifically, 39,019 RSUs were granted on March 8, 2026, and vest through March 8, 2029; 19,948 were granted on March 8, 2025, and vest through March 8, 2028; 2,849 were granted on March 8, 2025, and vest through March 8, 2027; and 7,237 were granted on March 8, 2024, and vest through March 8, 2027.

The Form 4 was signed by Christophe Cantenot as Attorney-in-Fact for Michael Jon Brown and filed on November 18, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reports a single open-market sale of 1,700 Dexcom common shares by EVP Michael Jon Brown on November 16, 2026, at $83.46 per share under a pre-established 10b5-1 plan, leaving him with 95,034 shares beneficially owned directly.